There were significant prognostic differences in 4 glioma subgroups (GBM IDH wildtype, GBM IDH mutant, Oligodendroglioma II-III, Astrocytoma II-III) (Figure 7). The gene discussed is IDH1; the disease is central nervous system cancer.